ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Foundation for Sarcoidosis Research Expands Scientific Advisory Board with 14 New Experts to Enhance Sarcoidosis Research and Patient Care

CHICAGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR), the leading international organization dedicated to finding a cure for sarcoidosis and improving care for sarcoidosis patients, is pleased to announce the appointment of fourteen new members to serve the organization’s Scientific Advisory Board (SAB). This brings the current SAB membership to 25 members.

The FSR SAB consists of world-renowned researchers, clinicians, and health industry leaders representing diverse professional disciplines with experience in advancing research, clinical trials, and the scientific understanding of sarcoidosis.

FSR Scientific Advisory Board Members

The FSR SAB provides guidance to the FSR Board of Directors and FSR leadership on scientific priorities and strategies, ensures FSR’s educational material reflects the most up-to-date scientific knowledge, and applies experience and rigor to ensure FSR’s grant funding is awarded towards the most innovative and scientifically promising research efforts.

“We are thrilled and honored to welcome these fourteen dedicated sarcoidosis experts to the SAB,” said Dr. Elliot Crouser MD, Physician and Professor at the Ohio State University and SAB Chair. “We look forward to advancing the mission of FSR, and the broad expertise reflected in this expanded advisory board should prove to be quite impactful.”

This panel reflects the most diverse set of expertise in FSR’s 25-year history. By bringing together experts in pulmonology, genetics, rheumatology, neurology, dermatology, and cardiology, FSR hopes to foster a multi-disciplinary approach to advancing the clinical, basic, and translational research needed to improve patient outcomes.

“Our new Scientific Advisory Board members’ expertise and dedication will be instrumental in advancing our mission to improve patient outcomes and advocate for innovative sarcoidosis research initiatives,” said Mary McGowan, FSR Chief Executive Officer. “Their diverse perspectives will help us navigate the complexities of modern medicine and ensure that our efforts remain patient-centered and strategic.”

The following new FSR SAB members begin their orientation in September 2024 with the official terms initiating in January 2025.

  • Nicholas Arger, MD
    Assistant Professor of Medicine in the Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California San Francisco
  • Matthew Baker, MD, MS
    Clinical Chief in the Division of Immunology and Rheumatology, Stanford University
  • Maneesh Bhargava, MBBS, PhD
    Associate Professor of Medicine in the Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Minnesota
  • David Birnie, MB, MRCP, MD
    Deputy Chief in the Division of Cardiology, University of Ottawa
  • Avrom Caplan, MD
    Clinical Assistant Professor in the Department of Dermatology, New York University
  • Jeffrey Gelfand, MD
    Associate Professor in the Division of Clinical Neurology, University of California San Francisco
  • Mridu Gulati, MD, MPH
    Associate Professor in the Division of Pulmonary, Critical Care and Sleep Medicine, Yale University
  • Sotonye Imadojemu MD, MPH
    Director of the Cutaneous Sarcoidosis and Granulomatous Diseases Clinic, Brigham and Women’s Hospital
  • Jordana Kron, MD
    Professor of Medicine in the Division of Cardiology, Virginia Commonwealth University
  • Courtney Montgomery, PhD
    Director for the Center for Biomedical Data Sciences, Oklahoma Medical Research Foundation
  • Natalia Rivera, PhD, MS
    Team Leader at the Center for Molecular Medicine and Research Specialist in the Respiratory Division, Karolinska Institute
  • Lobelia Samavati, MD
    Director of Center for Sarcoidosis and Interstitial Lung Disease, Wayne State University
  • Peter Sporn, MD
    Professor in the Division of Pulmonary and Critical Care Medicine, Northwestern University
  • Arthur Yee, MD, PhD
    Assistant Professor of Clinical Medicine, Cornell University and the Hospital for Special Surgery

For more information about the Foundation for Sarcoidosis Research, and sarcoidosis research and funding opportunities, please visit www.stopsarcoidosis.org.

About Sarcoidosis
Sarcoidosis is a rare inflammatory disease characterized by the formation of granulomas—tiny clumps of inflammatory cells—in one or more organs of the body. Despite increasing advances in research, sarcoidosis remains difficult to diagnose with limited treatment options and no known cure.

About the Foundation for Sarcoidosis Research (FSR)
The Foundation for Sarcoidosis Research (FSR) is the leading international organization dedicated to finding a cure for sarcoidosis and improving care for sarcoidosis patients through research, education, and support. Since its establishment in 2000, FSR has fostered over $6.5 million in sarcoidosis-specific research efforts. For more information and to join our community, visit www.stopsarcoidosis.org.

Contact:
Cathi Davis
312-341-0500
cathi@stopsarcoidosis.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e3f38b1a-791f-49b6-aa7c-092ad5e370e3


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.